Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Diseases 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 16Methotrexate 13Specimen Handling 12venetoclax 11Cyclophosphamide 11fludarabine 8Whole-Body Irradiation 8Biopsy 8merphos 7fludarabine phosphate 7calaspargase pegol 7Vincristine 7Hydrocortisone 7blinatumomab 6Granulocyte Colony-Stimulating Factor 6Dexamethasone 6revumenib 5Mycophenolic Acid 5Leucovorin 5Filgrastim 5Daunorubicin 5Calcium Dobesilate 5Asparaginase 5prednylidene 4dexamethasone acetate 4dexamethasone 21-phosphate 4deltacortene 4Thioguanine 4Tacrolimus 4Stem Cell Transplantation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Biphenotypic, Acute × cedazuridine × 90 days × Clear all
NCT04980404 2026-03-30

Inqovi Maintenance Therapy in Myeloid Neoplasms

Massachusetts General Hospital

Phase 1 Active not recruiting
22 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡